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Introduction
Idiopathic orbital inflammation syndrome (IOIS) is a rare condition and accounts for approximately 8% of 
orbital pathologies in childhood (1). IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory entity char-
acterized by infiltration of affected tissues with IgG4-positive plasma cells, elevated serum IgG4, storiform 
tissue fibrosis, and obliterative phlebitis affecting various organs, including the pancreas, biliary tract, liver, 
lungs, and/or retroperitoneum (2). IOIS as an initial presentation of an IgG4-RD resembles the most com-
mon organ manifestation of IgG4-RD in children (3). Generally, one or more organ systems can be involved 
in IgG4-RD, and individuals with involvement of two or more organs are diagnosed with systemic IgG4-RD 
(3). Middle-aged individuals are most commonly affected, but IgG4-RD has been reported across all ages. 
In children, IgG4-RD is extraordinarily rare and likely underdiagnosed. Approximately 40% of pediatric cases 
exhibited involvement of systemic disease in few reports published (3). Reflecting that IgG4-RD is a rela-
tively recently identified entity, the underlying pathomechanism, the role of increased serum IgG4, and the 
potential mechanistic differences between systemic and localized IgG4-RD are not known. The rarity and 
clinical variability of IgG4-RD affecting awareness among clinicians and the fact that the diagnostic criteria 
remain controversial significantly complicate the diagnostic process (3). Here, we report a unique case of 
IgG4-positive colitis in a 16-year-old patient with previously diagnosed IgG4-related IOIS. Clinical findings, 
diagnostic work-up, and treatment are discussed in the context of the literature available.
Case Presentation
A 16-year-old Caucasian girl was referred to the Department of Pediatrics with suspected orbital celluli-
tis for further diagnostic procedures and treatment initiation. The patient presented with swelling of the 
left upper eyelid and conjunctival irritation that had started 10 days prior to admission. Ophthalmologi-
cal examination showed limited bulbus movement and a hyperemic diffused papilla of the left eye with 
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IgG4-related disease (IgG4-RD) is an inflammatory disorder characterized by tumor-like swelling 
in one or more organs, elevated serum IgG4 levels, and histological alterations with infiltration of 
IgG4-positive plasma cells. IgG4-RD is rare and likely underdiagnosed in children. We report a case of a 
16-year-old girl with IgG4-positive colitis that developed weeks after IgG4-related ophthalmic disease 
and discuss diagnosis and treatment in the context of the literature available. Since the pathophysi-
ology of IgG4-RD is unknown, treatment options are empiric and, for the most part, untargeted. Sys-
temic corticosteroid treatment is the basis of anti-inflammatory treatment in IgG4-RD and induced 
early remission in our patient. During corticosteroid taper, the patient developed weight loss and 
intestinal inflammation. Histopathological assessment of the intestinal walls confirmed IgG4-positive 
colitis. Immune-modulating treatment with non-biologic (e.g., methotrexate (MTX) and mycophe-
nolate mofetil) or biologic (rituximab) disease-modifying antirheumatic drugs has been reported in 
treatment refractory or corticosteroid-dependent patients. The patient responded to treatment with 
anti-inflammatory therapy with food rich in TGF-β2 (modulen) and MTX. This is one of the first pedi-
atric patients reported with IgG4-related colitis extending the phenotype of pediatric IgG4-RD. Inter-
national collaboration to prospectively document clinical presentation and treatment responses may 
help to further establish the phenotype and treatment options and to raise awareness for IgG4-RD.
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normal visual acuity (Figure 1). General clinical 
examination showed no further pathological 
findings. The patient did not experience fever 
and had no personal or family history of malig-
nancy or autoimmune/inflammatory disease. 
Magnetic resonance imaging (MRI) using TIRM 
sequences showed perineural hyperinten-
sity of the left optical nerve and intraorbital 
muscles, as well as periocular inflammation 
affecting the left lacrimal gland (Figure 2). Con-
trast-enhanced T1-weighted fat suppression 
imaging showed heterogeneous enhance-
ment, suggesting an idiopathic orbital inflam-
matory disease, excluding lymphoma, cellulitis, 
or severe optical neuritis (Figure 3).
Routine blood laboratory tests remained large-
ly normal with normal complete blood count 
and differentiation, slightly elevated erythro-
cyte sedimentation rate (ESR) of 25 mm within 
the first hour, normal C-reactive protein (CRP) 
levels, normal serum lactate dehydrogenase 
levels, normal uric acid levels, normal free light 
chain κ/λ ratio, normal angiotensin-converting 
enzyme levels, and normal C3 and C4 levels. 
However, elevated serum IgG4 level (3.6 g/l, 
normal range 0.05-1.96 g/l) was determined. 
Thyroid function (thyroid-stimulating hor-
mone, triiodothyronine, and free thyroxine) 
was within the normal range. Antinuclear an-
tibodies (ANAs) were positive (1:640) with a 
granular pattern. Other autoantibodies tested 
(antineutrophil cytoplasmic antibodies, peri-
nuclear antineutrophil cytoplasmic antibodies, 
extractable nuclear antigens, Ro, La, Sm, and 
U1-RNP) were not detectable. Cerebrospinal 
fluid examinations remained normal, and in-
fectious disease screening (e.g., Epstein-Barr 
virus, Cytomegalovirus, Varicella-Zoster virus, 
Herpes Simplex virus 1/2, Enterovirus, Borrelia, 
Chlamydia, Mycoplasma DNA testing, and in-
terferon gamma release assays for tuberculosis 
infection) remained normal.
Based on the aforementioned findings from 
clinical, imaging, and laboratory examinations 
and significantly elevated IgG4 serum levels, 
IgG4-related ophthalmic disease was suspect-
ed, and systemic anti-inflammatory therapy 
with oral prednisolone (2 mg/kg/day) was 
initiated. With anti-inflammatory treatment, 
ophthalmologic status normalized after 8 
weeks, and slow tapering of prednisolone (>4 
months) was initiated.
Thereafter, the patient was followed up by the 
pediatric rheumatology department as an out-
patient every 3 months. She reported weight 
loss of 11 kg over the past 6-8 months (body 
mass index 15 kg/m2), lack of appetite, and 
upper gastric pain, as well as amenorrhea, 9 
months after the initial manifestation. She de-
nied stool irregularities or fever. Symptoms first 
began, but had been ignored and not shared, 
after oral prednisolone therapy was initiated 
but persisted after discontinuation of treat-
ment. Laboratory findings showed mild leu-
kopenia (2.8 Gpt/l, normal range 3.8-9.8 Gpt/l) 
and increased CRP (11 mg/l, normal range <5 
mg/l) and ESR (25 mm within the first hour). 
Serum IgG4 (2.3 g/l) and ANA (1:1280, granular 
pattern) remained elevated. Fecal calprotectin 
was elevated (1120 µg/g, normal: <50 µg/g) 
and suggested intestinal inflammation. A dihy-
drorhodamine oxidative burst tests delivered 
normal results and no evidence of chronic 
granulomatous disease/septic granulomatosis. 
Anti-endomysium autoantibodies (for celiac 
disease) were negative.
Ultrasonography unveiled diffuse intestinal 
wall thickening and signal hyperechogenici-
ty of the terminal ileum and cecum (4.3 mm) 
and inflammatory involvement of the attached 
mesenteries (Figure 4). MRI showed mild but 
generalized contrast enhancement of the 
small intestines and the colon (Figure 5). Vid-
eo capsule endoscopy unveiled many ulcers in 
the distal third of the small bowel. Colonosco-
py showed inflammatory changes of the entire 
colon (Figure 6). Tissue biopsies from the colon 
unveiled inflammatory infiltrates, crypt ab-
scesses, activated lymph follicles in the muco-
sal layer, and infiltrates of IgG4-positive plasma 
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Main Points
• Diagnosing IgG4-RD in children can be 
challenging because of its rarity, variable 
presentations, and multiple differential 
diagnoses.
• Idiopathic orbital inflammation syn-
drome resembles the most common 
organ manifestation of IgG4-RD in chil-
dren.
• Available consensus criteria for the di-
agnosis of IgG4-RD are validated only in 
adults, and there are no studies available 
analyzing IgG4-RD in children.
• Treatment is not standardized and based 
on personal experience, small case se-
ries, and expert opinion.
• Corticosteroids are usually the basis of 
treatment, and disease-modifying anti-
rheumatic drugs or B cell depletion may 
be used in severe or refractory cases. 
• The case presented here extends the 
phenotype of pediatric IgG4-RD by in-
testinal inflammation (colitis).
Figure 3. MRI orbital. Coronal T1-weighted 
image after contrast with fat saturation shows 
left enhancement retrobulbar and perineural 
involving the muscles.
Figure 2. MRI orbital. Coronal TIRM sequence 
shows left high signal perineural, retrobulbar, 
and peribulbar and in the glandula lacrimalis.
Figure 1. Unilateral optic disc edema and 
hyperemia with neuronal swelling, blurred 
disc margin, venous dilation and flow stasis, 
and absence of the venous pulsation of the 
affected left eye.
cells (>10 IgG4-positive plasma cells/standard 
HPF) (Figure 7). There was no evidence of neo-
plasia or infection. 
In the context of pre-existing IgG4-related or-
bital disease, the findings were interpreted as 
a new manifestation of (now systemic) IgG4-
RD. Anti-inflammatory nutritional therapy with 
food rich in TGF-β2 (Modulen) and systemic 
immunomodulatory therapy with methotrex-
ate (MTX) were suggested, but initially denied 
by the patient. Owing to persisting symptoms, 
increasing fecal calprotectin (>2000 µg/g), pro-
gressive intestinal wall changes on ultrasound, 
and persisting inflammatory alterations of the 
esophagus and gastric mucosa on endoscop-
ic re-evaluation (8 weeks later), the patient 
agreed to treatment with Modulen (2.5-3 l/day 
for 8 weeks) and MTX (12.7 mg/m2). As a result, 
symptoms improved (including weight gain of 
3.5 kg in 2 months, 8% of body weight), and 
inflammatory laboratory parameters (CRP and 
ESR) normalized. Nevertheless, serum levels of 
IgG4 remained elevated (2.7 g/l). 
Unfortunately, further consultations in our pe-
diatric rheumatology department were can-
celed, medication with MTX was discontinued 
after 3 months of treatment, and the patient 
was lost to follow-up.
Literature Review and Discussion
Epidemiology and clinical picture
Though overall rare, inflammatory orbital dis-
ease is the most common organ manifestation 
of IgG4-RD in children (3). IgG4-RD was first de-
scribed in 2003 as a clinical entity that is char-
acterized by systemic fibrotic inflammation (4). 
To our knowledge, there are no retrospective 
or prospective studies available investigating 
children with IgG4-RD. Several reports dis-
cussed individual cases of childhood IgG4-RD 
(5-7). Karim et al. (3) reviewed published pedi-
atric cases and found that the median age at 
onset is approximately 13 (3-16) years, and that 
approximately 2/3 (64%) of cases affect girls 
and young women. Patients developed tumor-
ous lesions that initially raised the suspicion of 
malignancy in a substantial subset of cases.
Distribution of organ manifestations in IgG4-
RD is comparable between children and adults. 
Generally, all organs can be involved, whereas 
the orbit, pancreas, biliary ducts, bronchopul-
monary system, thyroid, salivary glands, lymph 
nodes, and mesenteries are most commonly 
affected (3). Inflammation of the orbital region 
can manifest as ocular myositis, dacryoadenitis, 
perineuritis of the optic nerve, and orbital in-
flammatory pseudotumor (8).
Pathophysiology
The pathophysiology of IgG4-RD is unknown 
as briefly mentioned in the Introduction sec-
tion. Ongoing inflammation in IgG4-RD results 
in progressive fibrosis and irreversible organ 
damage (4). Several pathophysiological con-
cepts have been proposed. Currently unknown 
immunologic trigger mechanisms (e.g., foreign 
pathogen- and/or damage-associated mo-
lecular patterns) may activate innate immune 
cells, mainly monocytes and basophils, which 
in turn induce adaptive immune responses in-
cluding B cell activation and IgG4 production 
(8). A number of infectious pathogens have 
been suggested as potential immunologic 
triggers in IgG4-RD, including Helicobacter py-
lori (9), pulmonary Paragonimus westermani in-
fections, and/or in helminth infections. Howev-
er, no specific pathogen-associated molecular 
patterns or damage-associated molecular pat-
terns contributing to IgG4-RD have yet been 
identified. Activated basophils may enhance T 
helper subset 2 (Th2) cell-driven inflammation. 
Increased numbers of Th2 lymphocytes and 
regulatory T cells (Treg) have been observed 
in peripheral blood of patients with IgG4-RD, 
and tissue sections from patients showed in-
creased expression of Th2- and Treg-associat-
ed cytokines interleukin (IL)-5, IL-13, IL-10, and 
transforming growth factor (TGF)-β (4). Patho-
logically activated Th2 lymphocytes may result 
in the recruitment of Treg cells which secrete 
IL-10 and TGF-β, cytokines that mediate fibro-
blast activation resulting in tissue fibrosis (4, 
10). Finally, the role of IgG4 antibodies in the 
pathogenesis remains unclear (effector vs. by-
product). Since it is mainly viewed as an anti-in-
flammatory molecule, the direct involvement 
of IgG4 in organ inflammation is currently de-
bated (8, 11).
Diagnosis of IgG4-RD
Based on the rarity of IgG4-RD and associated 
low awareness among providers, diagnosing 
IgG4-RD can be challenging, and cases may be 
missed. A set of diagnostic criteria for IgG4-RD 
was proposed following a consensus process 
by Umehara et al. (12), which can be applied 
after exclusion of important differential diag-
noses (e.g., cancers, systemic vasculitis, and 
sarcoidosis) (Figure 8). However, criteria were 
proposed based on experience in adult Japa-
nese cohorts and (to our knowledge) have not 
been tested prospectively in Asian or non-Asian 
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Figure 7. Immunohistochemistry of a colon 
biopsy (40×). Inflammatory infiltrate in the mu-
cosal layer, rich in IgG4-positive plasma cells 
(marked with arrow) (>10 IgG4-positive plasma 
cells/HPF).
Figure 4. Ultrasonography showing intesti-
nal wall thickening, diffuse layering of the ter-
minal ileum (4.3 mm), and an inflammatory 
reaction of the attached mesenteric.
Figure 6. Colonoscopy. Active colitis, erosions 
with fibrin exudates, erythema, and near com-
plete loss of normal vascular pattern.
Figure 5. MRI abdomen. Transversal T1-weight-
ed image after contrast with fat saturation 
shows mild enhancement of the wall of the 
colon and small intestines.
populations. Therefore, their diagnostic val-
ue, particularly in Caucasian patients, remains 
unknown. Deshpande et al. (13) suggested a 
pathology score for IgG4-RD also based on a 
consensus process (Figure 9). They emphasize 
that on the one hand, histopathological criteria 
provide evidence for the diagnosis, but on the 
other hand, need to be correlated with clini-
cal und radiographic characteristics to ensure 
the diagnosis (13). They place more emphasis 
on appropriate morphological features and 
suggest that >10 IgG4+ plasma cells/HPF are 
required to secure the diagnosis of IgG4-RD, 
but for example (especially depending on the 
organs involved), IgG4+/IgG+ plasma cell ratios 
<40% do not exclude IgG4-RD. On the other 
hand, a number of non-IgG4-RD entities can be 
associated with IgG4+/IgG+ plasma cell ratios 
>40%. Of note, conditions associated with ele-
vated serum IL-6 concentrations, such as Castle-
man’s disease, rheumatoid arthritis, and other 
immune-mediated conditions, may also exhibit 
increased numbers of IgG4+ plasma cells, tissue 
IgG4+/IgG+ plasma cell ratios >40%, and elevat-
ed serum IgG4 concentrations (14, 15). 
In daily practice, the diagnosis of IgG4-RD may 
be suspected in patients with swelling or mass in 
one or more organs on clinical examination and/
or diagnostic imaging in the context of elevated 
serum IgG4 (>1.35 g/l). However, the positive 
predictive value of elevated serum IgG4 is limited 
since a significant proportion of children exhibit 
(at least mildly) elevated serum IgG4 levels (up 
to 70%). Similar observations have been made in 
the adult population (up to 30%-50%) (3, 16). 
Thus, histopathology and associated afore-
mentioned scores play a central role in diag-
S24
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Figure 8. Diagnostic criteria for IgG4-RD as proposed by Umehara et al (8, 13).
Organ involvement
serum IgG4 >1.35 g/L
Definite IgG4-RD Possible IgG4-RD Probable IgG4-RD Denial IgG4-RD
IgG4+ counts >10 cells/hpf and/or
IgG4+/IgG+cell ratio >40%









Figure 9. Diagnostic terminology for IgG4-related disease as suggested by Deshpande et al. (14).
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nosing IgG4-RD. In addition to IgG4-positive 
plasma cells, storiform fibrosis and obliterative 
phlebitis can be present and are predomi-
nant in pancreatic manifestations of IgG4-RD. 
However, fibrosis and angiopathy are rarely 
observed in intestinal lesions or lymph nodes 
(17). Indeed, the diagnostic criteria published 
by Umehara et al. (12) did not include gastroin-
testinal diseases as part of IgG4-RD. Disease-as-
sociated intestinal inflammation has been 
established as part of IgG4-RD since then that 
usually does not entail mass-like formations, 
dense fibrosis, or obliterative phlebitis, all of 
which are considered histopathological char-
acteristics that are required to be met to make 
a diagnosis based on the criteria proposed by 
Deshpande et al. (13, 18). 
IgG4-positive plasma cells can be present in 
inflamed tissues from patients with differential 
diagnoses that share symptoms with IgG4-
RD and may also present with elevated IgG4 
serum levels, thereby further complicating 
the situation. Thus, alternative diagnosis (e.g., 
xanthogranulomatous disease, granulomatosis 
with polyangiitis, and sarcoidosis), required to 
be thoroughly excluded before the diagnosis 
of IgG4-RD, is made (19). Few studies detect-
ed high levels of mucosal and serum IgG4 in 
patients with inflammatory bowel disease 
(IBD) (17). Thus, it is matter of debate whether 
increased serum IgG4 and (isolated) intesti-
nal infiltration with IgG4-positive plasma cells 
should trigger the diagnosis of IgG4-RD rather 
than other “classical” forms of IBD (20). Finally, 
since IgG4-positive plasma cell infiltrates can 
be seen in tissues surrounding cancer cells and 
IgG4-RD is characterized by tumorous swelling, 
malignancies required to be considered and 
excluded before the diagnosis of IgG4-RD can 
be made (4).
Our patient initially presented with singular 
solid-organ inflammatory disease of the orbit. 
Owing to diffuse inflammation affecting the 
optical nerve and surrounding musculature, 
we decided not to conduct surgical interven-
tions to collect tissue for histopathology. De-
velopment of inflammatory symptoms in the 
gastrointestinal tract after an initially successful 
corticosteroid treatment controlling intraor-
bital inflammation resulted in classification as 
systemic IgG4-RD. Indeed, histopathological 
assessment of the intestinal walls delivered 
dense inflammatory infiltrates with lymph 
follicles in the mucosal layer that were rich in 
IgG4-positive plasma cells with >10 IgG4-posi-
tive plasma cells/HPF. However, we did not see 
an IgG4/IgG plasma cell ratio >40%. While this 
may offer room for debate considering the di-
agnostic criteria suggested by Umehara et al. 
(12), Deshpande et al. (13) consider an IgG4/
IgG plasma cell ratio <40% as insufficient to 
exclude IgG4-RD (21). Indeed, we feel that the 
diagnosis of IgG4-RD is justified based on id-
iopathic orbital inflammation, significantly ele-
vated serum IgG4 levels, intestinal involvement 
with increased IgG4-positive plasma cell num-
bers, and rapid response to immune-modulat-
ing treatment (see below) (Figure 10).
Treatment
Treatment of IgG4-RD is empiric and based on 
personal experience of healthcare profession-
als, expert opinion, case reports, and retrospec-
tive case series. Usually, treatment decisions 
are adapted toward the site of inflammation 
and the extent of organ involvement. In the 
past, clinically “mild” single organ involvement 
usually triggered clinical follow-up without 
anti-inflammatory treatment. More recently, 
“mild” manifestations have been considered 
early disease stages, and anti-inflammatory 
treatment is usually offered to all patients with 
IgG4-RD (3). More severe cases ask for a rapid 
introduction of immune-modulating therapy. 
Corticosteroids, usually prednisone or prednis-
olone, are used for first-line therapy. However, 
there is no consensus on dose or treatment 
duration. Karim et al. (3) suggested oral pred-
nisolone (0.5-2 mg/kg/day) to induce rapid 
remission, followed by a slow taper over 3-6 
months to avoid relapse of disease. Non-bio-
logic disease-modifying antirheumatic drugs 
(DMARDs), including mycophenolate mofetil, 
azathioprine, or MTX, have been suggested 
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Figure 10. Summarized diagnostic and histopathological criteria for IgG4-related disease by Umehara et al. (13) and Deshpande et al. (14). Criteria 
met by the index patient are marked with a checkmark.



























3. Histopathological criteria (Deshpande et al. (14))
- Lymphocyte and plasma-cell infiltration
- Tissue fibrosis
- Obliterative phlebitis
- >10 IgG4+ plasma cells/hpf
- IgG4+/IgG-plasma cell ratio >40%




6. Exclusion of differential diagnoses, e.g. malignant 
tumors (cancer or lymphoma), granulomatosis with 
polyangiitis, sarcoidosis
5. Response to glucocorticoid therapy
2. Serum IgG4-Concentration >1.35 g/L
as steroid-sparing agents and/or in patients 
refractory to corticosteroids alone (22). Car-
ruthers et al. (23) evaluated rituximab as a treat-
ment alternative for resistant cases in adults. 
Out of 30 IgG4-RD patients treated with two 
doses of rituximab (1000 mg each), a total of 
97% responded to therapy, 77% achieved the 
primary outcome (reduced disease activity off 
corticosteroids), and 47% reached complete 
remission (Figure 11).
Our patient initially received treatment with 
oral prednisolone (2 mg/kg/day) to control 
intraorbital inflammation. Subsequent inflam-
matory involvement of the intestine resulted 
in re-establishment of immune-modulating 
treatment with corticosteroids now accompa-
nied with Modulen and MTX. Early response to 
treatment resulted in normalized inflammatory 
parameters and weight gain within weeks.
Published data on treatment duration and 
disease monitoring are limited. For disease 
monitoring, imaging (ultrasonography or MRI) 
of affected organs is essential, whereas moni-
toring of serum IgG4 levels has not been vali-
dated (4). Unfortunately, the patient was lost to 
follow-up 3 months after remission induction 
and decided to discontinue treatment. Thus, 
we cannot report long-term outcomes.
Conclusion
To our knowledge, this is the first report of a 
pediatric patient with a combination of or-
bital and intestinal involvement in IgG4-RD. 
Healthcare providers should consider IgG4-RD 
in cases of otherwise unexplained inflammato-
ry alteration or tumorous lesions. The rarity of 
disease particularly in childhood and variable 
clinical presentations contribute to diagnostic 
delay, underdiagnoses, and/or even misdiag-
noses. Early diagnosis and treatment are es-
sential to minimize organ damage. Treatment 
with corticosteroids is usually effective, but 
maintenance therapy with non-biologic and/or 
biologic DMARDs may be required. Internation-
al collaboration is needed to produce reliable 
data in this rare condition and to validate the 
proposed diagnostic criteria and treatment op-
tions for children (but also adults) with IgG4-RD.
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